Immunological mechanisms of intravesical chitosan/interleukin-12 immunotherapy against murine bladder cancer. – UroToday
|
Immunological mechanisms of intravesical chitosan/interleukin-12 immunotherapy against murine bladder cancer.
UroToday There is a critical unmet clinical need for bladder cancer immunotherapies capable of inducing durable antitumor immunity. We have shown that four intravesical treatments with a simple co-formulation of interleukin-12 and the biopolymer chitosan not … |
